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Notch signalling is an evolutionarily conserved 
cell‑to‑cell communication cascade that was originally 
identified in flies1. Signalling is mediated by Notch 
ligand–receptor interactions between neighbouring 
cells. Flies have a single type I transmembrane‑bound 
receptor that can be activated by two transmembrane‑
bound ligands named Serrate and Delta. Mammals 
possess four receptors (Notch 1–4) that are bound by 
five ligands of the Jagged family and Delta‑like family 
(Jagged 1 and Jagged 2, and Delta‑like ligand 1 (DLL1), 
DLL3 and DLL4). The biochemical details of the canoni‑
cal Notch signalling cascade have been comprehensively 
reviewed2,3 (BOX 1). In recent years, evidence has been 
found of non‑canonical Notch signalling that does not 
require the RBPJ transcriptional mediator complex. These 
non‑canonical signal transduction pathways may occur 
in the absence of receptor cleavage or through crosstalk 
with other signalling pathways (including the nuclear 
factor‑κB (NF‑κB), transforming growth factor‑β 
(TGFβ) and hypoxia‑induced signalling pathways)4–6.
Genome‑wide expression and chromatin immuno‑
precipitation (ChIP) studies suggest the existence of a 
large number of genes that can be regulated by Notch7,8. 
Despite the large number of potential Notch target 
genes, the best‑characterized are the basic helix–loop–
helix (bHLH) transcriptional repressors of the hairy 
enhancer of split (HES) and hairy‑related (HRT) protein 
families9. As Notch signalling is recurrently either used 
for the generation and development of diverse blood cell 
lineages or used during peripheral immune responses 
following pathogenic infections, one of the major chal‑
lenges is to identify the crucial driver target genes in 
these different settings in order to better understand 
how Notch exerts its pleiotropic functions.
The best‑studied functions of Notch signalling in 
haematopoiesis are its essential roles during lympho‑
cyte development, in particular during T cell lineage 
commitment and maturation in the thymus, and during 
marginal zone B (MZB) cell development in the spleen. 
More recently, Notch has also emerged as a key player in 
dendritic cell (DC) homeostasis and in the development 
of several lymphocyte subsets belonging to the innate 
immune system. In this Review, we discuss the role of 
Notch in the development of these specific blood line‑
ages. Moreover, we highlight recent advances pertaining 
to Notch signalling in subsets of mature CD4+ and 
CD8+ T cells in peripheral lymphoid tissues.
Developmental roles for Notch
Notch signalling in T  cell and MZB  cell develop-
ment. Bone marrow progenitors seed the thymus via 
the bloodstream, where they are instructed to adopt 
a T cell fate and further differentiate into αβ T cells 
or γδ T cells before emigrating to the periphery. The 
first insights of Notch function in this context were 
derived from complementary genetic loss‑of‑function 
and gain‑of‑function studies. Inducible inactivation of 
Notch 1 or recombination signal binding protein for 
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Abstract | Coordinated function of the innate and adaptive arms of the immune system in 
vertebrates is essential to promote protective immunity and to avoid immunopathology. The 
Notch signalling pathway, which was originally identified as a pleiotropic mediator of cell 
fate in invertebrates, has recently emerged as an important regulator of immune cell 
development and function. Notch was initially shown to be a key determinant of cell-lineage 
commitment in developing lymphocytes, but it is now known to control the homeostasis of 
several innate cell populations. Moreover, the roles of Notch in adaptive immunity have 
expanded to include the regulation of T cell differentiation and function. The aim of this 
Review is to summarize the current status of immune regulation by Notch. A better 
understanding of Notch function in both innate and adaptive immunity will hopefully 
provide multiple avenues for therapeutic intervention in disease.
R E V I E W S
NATURE REVIEWS | IMMUNOLOGY  VOLUME 13 | JUNE 2013 | 427
© 2013 Macmillan Publishers Limited. All rights reserved
immunoglobulin κJ region (RBPJ; also known as CSL 
in humans) in bone marrow progenitors results in a 
complete block of T cell development, accompanied by 
the accumulation of ectopic B cells in the thymus10,11. 
By contrast, the constitutive expression of active forms 
of Notch induced ectopic T cell development and sup‑
pressed B cell development in the bone marrow12. Since 
then, multiple studies, including studies interfering with 
Notch signalling by transgenic expression of Notch 
modulators (such as Fringe proteins, Deltex 1 and Notch‑
regulated ankyrin repeat‑containing protein (NRARP)) 
or studies expressing dominant‑negative forms of the 
transcriptional co‑activator Mastermind‑like protein 1 
(MAML1), have confirmed the original findings13–16. This 
led to a model in which Notch 1 ensures T cell lineage 
commitment by inhibiting the other multiple cell‑fate 
potentials of thymus‑seeding cells, including myeloid 
cell and B cell potential, as well as conventional DC 
and plasmacytoid DC potential17–20 (FIG. 1). Although 
the transcription factor HES1 was recently shown to be 
an important Notch mediator for T cell lineage commit‑
ment, conditional inactivation of HES1 does not lead 
to the accumulation of B cells or DCs in the thymus21. 
This result suggests that Notch signalling specifies 
the T cell lineage through the activation of additional 
downstream target genes.
Although DLL1 and DLL4 can both instruct bone 
marrow cells to adopt a T cell fate in vitro, genetic 
ablation studies showed that in vivo the instructive signal 
is triggered through the interaction of Notch 1‑express‑
ing thymus‑seeding cells with DLL4‑expressing thymic 
epithelial cells22–26. Notch signalling is highest in imma‑
ture αβ T cells (including in early thymic progenitors 
(ETPs), double‑negative 2 (DN2) thymocytes and DN3a 
thymocytes) up to the DN3 stage, at which cells have to 
pass a critical checkpoint known as β-selection27. In these 
immature thymocytes, Notch 1, but not HES1, is con‑
tinuously required to restrict developing αβ T cells to 
the T cell lineage21. However, once specified, γδ T cells 
are less dependent on Notch signalling, at least in the 
mouse. For human thymocytes the situation seems to 
be different, as γδ T cells require higher levels of Notch 
signalling compared with developing αβ T cells28,29. 
After thymocytes successfully pass β‑selection, they 
immediately downregulate Notch  1 expression, a 
process that is triggered by the pre-T cell receptor (pre‑
TCR)‑mediated induction of the HLH transcription 
factor inhibitor of DNA binding 3 (ID3). ID3 inhibits 
E2A‑induced transcription of Notch 1 (REF. 30). As a 
consequence, double‑positive (CD4+CD8+) thymo‑
cytes have very low levels of Notch signalling, which is 
presumably required to avoid interfering with positive 
and negative selection in double‑positive thymocytes, 
as well as to avoid the oncogenic properties of Notch 
signalling and its targets8 (FIG. 1).
Another well‑established role for Notch signalling dur‑
ing lymphocyte development is its role in the specification 
of two different major subsets of splenic B cells, namely 
MZB cells and follicular zone B cells. Follicular zone 
B cells participate in T cell‑mediated immune responses. 
These circulating B cells represent the majority of B cells 
within the spleen, where they localize to B cell follicles, 
hence the name follicular zone B cells. By contrast, MZB 
cells are found in the outer region of the splenic white 
pulp between the marginal sinus and the red pulp31. 
They are important in driving fast and vigorous T cell‑ 
independent antibody responses to blood‑borne patho‑
gens32. Moreover, they express high levels of CD1d, thus 
allowing them to capture and present lipid antigens to 
invariant natural killer T cells. Both MZB cells and follicular 
Box 1 | A brief overview of Notch signalling
Mammals possess four Notch receptors (Notch 1–4) that are bound by five ligands  
of the Jagged, and Delta-like family (Jagged 1 and Jagged 2, and Delta-like ligand 1 
(DLL1), DLL3 and DLL4). Newly synthesized receptors are proteolytically processed  
in the Golgi during their transport to the cell surface by a furin-like convertase.  
This results in the generation of heterodimeric receptors present at the cell surface  
(see the figure). Signalling is initiated by ligand binding to the receptors, which 
subsequently undergo two successive proteolytic cleavages; the first is mediated  
by disintegrin and metalloproteinase domain-containing protein (ADAM) family 
metalloproteinases at the extracellular S2 cleavage site close to the transmembrane 
domain. This results in the shedding of the extracellular part of the receptors,  
which are endocytosed by the ligand-expressing cell. This process requires 
monoubiquitylation of the cytoplasmic tail of the ligands by E3 ubiquitin ligases of 
the Mindbomb and Neuralized families. After a successful S2 cleavage and shedding 
of the extracellular domain, a last cleavage within the transmembrane domain is 
triggered by the γ-secretase activity of a presenilin multi-protein complex, thus 
liberating the Notch intracellular domain (NICD). This is a rate-limiting step during 
Notch activation, which can be pharmacologically blocked by small-molecule 
γ-secretase inhibitors112. Once the NICD is liberated, it translocates to the nucleus 
and binds to the transcription factors of the recombination signal binding protein 
for immunoglobulin κJ region (RBPJ) family (also known as CSL in humans, 
Suppressor of hairless in Drosophila melanogaster, and LAG-1 in Caenorhabditis 
elegans). When bound to RBPJ, the NICD recruits additional co-activators, including 
mastermind proteins (MAML1–3) and p300 in order to induce transcriptional 
expression of downstream target genes. Furthermore, Notch signalling is regulated 
at multiple levels. For example, Notch receptors undergo post-translational 
modifications by Fringe family glycosyltransferases. These transferases add 
N-acetylglucosamine to O-fucose residues present in certain epidermal growth 
factor (EGF) repeats of the extracellular domain of Notch receptors113. This 
influences the relative binding avidity of ligand–receptor pairs, which translates 
into different efficiencies or signalling strength of Notch receptors114–116.
Proteins shown in red are co-repressors of RBPJ; those shown in green are cofactors for RBPJ.
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This is the assembly of proteins 
including RBPJ (known as CSL 
in humans), the Notch 
intracellular domain (NICD) and 
transcriptional co-activators 
such as Mastermind-like 
proteins (MAMLs), histone 
acetyltransferases and the 
mediator complex in order  
to generate an active 
transcriptional complex on 
target promoters.
β-selection
During development, immature 
double-negative 3 thymocytes 
have to pass a critical 
checkpoint known as 
β-selection, or the pre-T cell 
receptor (pre-TCR) checkpoint, 
at which they have to signal  
via the pre-TCR to continue 
their development.
Pre-T cell receptor
(Pre-TCR). The pre-TCR consists 
of a productively re-arranged 
TCRβ chain associated with 
CD3 components and an 
invariant pre-TCRα chain.
Invariant natural killer 
T cells
These are a specialized subset 
of innate-like lymphocytes  
that share properties of both 
natural killer (NK) cells and 
T cells. They express 
NK-related molecules and 
T cell receptors (TCRs), and 
their TCRs recognize self  
and foreign lipids presented  
on CD1d molecules.
B cells originate from B cell progenitors in the bone mar‑
row. When B cells migrate out of the bone marrow, they 
colonize secondary lymphoid organs, including the 
spleen, where they further mature through transitional 
stages (known as T1 and T2), before ultimately giving rise 
to mature follicular B cells or MZB cells in the spleen.
The specification process of T2 B cells into either of the 
two mature B cell fates is influenced by multiple factors31. 
However, conditional gene‑targeting experiments of mul‑
tiple Notch components revealed that the specification of 
MZB cells is strictly dependent on DLL1‑mediated Notch 2 
signalling (FIG. 1). Mice with conditional inactivation of 
Figure 1 | Notch signalling in immune cell development. Bone marrow haematopoietic stem cells (HSCs) give rise to 
multipotent progenitors (MPPs) before differentiating into common myeloid progenitors (CMPs) and common ly ph id 
progenitors (CLPs). CLPs migrate from the bone marrow to the thymus, where thymic epithelial cells that express 
Delta-like ligand 4 (DLL4) trigger canonical Notch 1 signalling in early thymic progenitors (ETPs). This Notch 1 signal is 
essential for T cell lineage commitment and is further required during early phases of thymocyte differentiation up to the 
double-negative 3 (DN3) stage. Active Notch signalling during these early stages of T cell development inhibits other 
lineage potentials, such as B cell and myeloid cell (including dendritic cell (DC)) potential. During β-selection, Notch 
signalling is turned off as a consequence of pre-T cell receptor signalling. Thus subsequent stages of T cell development 
exhibit very low levels of Notch signalling. Notch was also suggested to influence the development of regulatory T (T
Reg
) 
cells (specifically, thymic T
Reg
 cells). In bone marrow-residing CLPs, Notch signalling must be switched off to allow proper 
B cell development. After migration of immature B cells to the spleen, interaction of DLL1 with Notch 2 (mediated by 
recombination signal binding protein for immunoglobulin κJ region (RBPJ)) induces Notch signalling in transitional B (T2) 
cells to specify marginal zone B cells as opposed to follicular B cells. The vast majority of DCs are derived from CMPs in the 
bone marrow, which give rise to macrophage–DC progenitors (MDPs). Subsequently, common DC progenitors (CDPs) 
develop into pre-DCs, seeding lymphoid and non-lymphoid organs via the bloodstream. In the spleen these pre-DCs are 
specified into multiple DC subsets, including classical DCs (cDCs) and plasmacytoid DCs (pDCs). Splenic CD8− endothelial 
cell-selective adhesion molecule (ESAM)+ DCs and CD103+CD11b+ DCs in the lamina propria of the intestine require 
Notch signalling mediated by the Notch 2 receptor. DP, double-positive; TEC, thymic epithelial cell.
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DLL1 or Notch 2 have severely decreased numbers of 
MZB cells33,34, a phenotype that was also observed in RBPJ‑
mutant35, MAML1‑mutant^^36,37, Mind bomb 1‑mutant^^38 
and disintegrin and metalloproteinase domain‑containing 
protein 10 (ADAM10)39‑mutant mice. Taken together, 
these genetic loss‑of‑function experiments strongly sug‑
gest that this process is mediated via canonical Notch 
signalling, although, surprisingly, HES1 is not required21. 
Inactivation of Msx2‑interacting protein (MINT; also 
known as SPEN), which is a negative regulator of Notch 
signalling, resulted in increased MZB cell numbers40, 
which is an additional confirmation of Notch being an 
important regulator of MZB cell specification. Moreover, 
the cooperative action of two Fringe family members 
(Lunatic fringe and Manic fringe) seems to be necessary 
to strengthen the presumably weak interaction between 
MZB cell precursors and DLL1‑expressing splenic niche 
cells41. Although it is clear that DLL1 is the non‑redundant 
ligand that triggers a Notch 2 signal to specify MZB cells 
in the spleen, the nature of the DLL1‑expressing cells is 
still unclear. Although non‑haematopoietic cells33 and, in 
particular, endothelial cells have been shown to express 
DLL1 in the red pulp of the spleen41, it remains to be shown 
whether DLL1‑expressing endothelial cells are indeed the 
splenic niche cells that support MZB cell development.
Notch signalling in DC development. DCs are a subset 
of haematopoietic cells that are specialized in antigen 
presentation. Until recently the only evidence for Notch 
involvement in DC differentiation was based on in vitro 
studies in which DC development could be influenced 
by the overexpression of Notch receptors or ligands 
and pharmacological manipulation by Notch inhibi‑
tors. More recently, loss‑of‑function studies have pro‑
vided conclusive evidence that Notch signalling plays 
an important part in DC development and homeosta‑
sis. Conditional inactivation of RBPJ or Notch 2 specifi‑
cally in DCs led to a selective reduction of a subset of 
DCs in the spleen but not in other lymphoid tissues42,43. 
Splenic DCs comprise a plasmacytoid DC compartment 
as well as several subsets of conventional DCs that can 
be identified by their differential expression of CD8 and 
CD11b, together with their expression of other markers, 
such as the adhesion molecule endothelial cell‑selective 
adhesion molecule (ESAM). In the absence of Notch 2, 
only the CD8−CD11b+ESAM+ DC subset was missing, 
whereas other DC subsets (both conventional and plas‑
macytoid) were not affected43 (FIG. 1). The requirement 
for Notch 2 in the maintenance of splenic DCs seems 
to be non‑redundant, as conditional inactivation of 
Notch 1 either in DCs43 or in all haematopoietic cells44,45 
does not affect DC numbers.
The Notch ligand responsible for directing splenic 
DC development remains to be identified. However, it 
is noteworthy that the CD8−CD11b+ESAM+ DC subset 
that depends on Notch 2 signalling is localized to the 
splenic marginal zone in close proximity to stromal cells 
expressing DLL1 (REF. 42). As MZB cell development in 
the spleen is strictly dependent on DLL1‑expressing 
stromal cells33 it is tempting to speculate that splenic DC 
development is likewise dependent on DLL1.
In addition to splenic DCs, a subset of DCs located in 
the lamina propria of the intestine is strongly reduced in 
the absence of Notch 2. These DCs have a CD103+CD11b+ 
phenotype and are believed to be specialized in antigen 
capture and transport to the mesenteric lymph nodes, 
where they can activate CD4+ helper T cells, and in par‑
ticular those secreting interleukin‑17 (IL‑17): that is, 
T helper 17 (TH17) cells. Consistent with this model, 
TH17 cell numbers are also decreased in the intestine fol‑
lowing DC‑specific conditional inactivation of Notch 2 
(REF. 43). Taken together, these recent studies reveal a 
novel and tissue‑specific role for Notch 2 in the homeo‑
stasis of distinct DC subsets and consequent control 
of T cell priming (FIG. 1).
Notch signalling in innate lymphoid cell development. 
More recently, the development of another set of inter‑
esting immune cells, the innate lymphoid cells (ILCs), 
was reported to be influenced by Notch signalling. ILCs 
encompass a novel family of haematopoietic effector 
cells that have important functions in innate immune 
responses to infectious microorganisms, in the genera‑
tion of secondary lymphoid organs and in tissue remod‑
elling after tissue injury or infection. ILCs develop from 
common lymphoid progenitors, but unlike B cells and 
T cells they do not rearrange immunoglobulin genes 
or express antigen‑specific receptors. In general they 
can be subdivided in three major subclasses (group 1, 
group 2 and group 3 ILCs), depending on whether they 
express TH1‑type, TH2‑type or TH17‑type cytokines, 
respectively46,47. Whereas natural killer (NK) cells, 
which belong to the group 1 ILCs, have cytotoxic activ‑
ity and functions, lymphoid tissue‑inducer (LTi) cells (a 
type of group 3 ILC) are essential for the development 
and generation of secondary lymphoid organs. LTi cell 
development is dependent on retinoid‑related orphan 
receptor‑γt (RORγt)48. In this context, Notch signalling 
was shown to be transiently required for the generation 
of fetal α4β7+ LTi cell progenitors before upregulation 
of RORγt. Subsequently, Notch signalling must be down‑
regulated again to allow the expression of RORγt and 
the final maturation of LTi cells49.
More recent additions to the RORγt‑dependent 
group 3 ILC subclass are IL‑22‑producing ILCs, which 
have been referred to as ILC22s and which share hall‑
marks of LTi cells and NK cells. The ILC22s are non‑
cytotoxic but express the NK marker NKp46 and produce 
high levels of IL‑22, and are therefore also known as NK22 
cells. They are mostly found in mucosal tissues (such as 
the lamina propria of the intestine, Peyer’s patches or ton‑
sils) in humans and mice, where they induce early protec‑
tive immune responses to colitis‑inducing pathogens50,51. 
Both human and mouse ILC22s express the transcription 
factor aryl hydrocarbon receptor (AHR), which becomes 
activated by xenobiotics (that is, chemical compounds 
that are found in an organism but that are not normally 
produced by it, such as polycyclic aromatic compounds). 
On activation and ligand binding, AHR translocates 
from the cytoplasm to the nucleus and binds to pro‑
moter regions containing so‑called xeno biotic response 
elements in order to induce target gene expression. 
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Interestingly, both NOTCH1 and NOTCH2 promoters 
contain such xenobiotic response elements, and expres‑
sion of their transcripts is induced in vivo by the admin‑
istration of an AHR ligand. Conditional inactivation of 
the transcription factor RBPJ, which mediates signalling 
downstream of all Notch receptors, resulted in a substan‑
tial reduction of NKp46+ ILCs in the lamina propria of 
the intestine but not in Peyer’s patches. Similar results 
were obtained with Ahr‑mutant mice52,53, suggesting that 
the development and/or expansion of NKp46+ ILCs in 
certain microenvironments is mediated by AHR‑induced 
Notch signalling54.
Another RORγt‑dependent but NKp46‑negative sub‑
set of ILCs is mostly found in the colon of mice during 
inflammation. These cells express high levels of IL‑17 in 
response to IL‑23, which is responsible for gut pathol‑
ogy55. Whether this particular subset of ILCs is also 
dependent on Notch is currently unknown.
Nuocytes, which are also known as ILC2s because 
of their ability to secrete high levels of type 2 cytokines, 
including IL‑5 and IL‑13, are RORα‑dependent cells. 
They proliferate in response to IL‑25 and IL‑33 admin‑
istration or in response to pathogens, including parasitic 
helminths, viruses and fungi56–58. They have an impor‑
tant role in type 2‑mediated immunity. For example, 
activation of these cells by the administration of IL‑25 
is sufficient to clear parasitic worms even in the absence 
of adaptive immunity57. In vivo, common lymphoid 
progenitor (CLP) reconstitution assays revealed that 
nuocytes are derived from CLPs in the bone marrow. 
However, they can also be generated in vitro under 
appropriate culture conditions. CLPs, along with DN1 
and DN2 thymocytes, develop into nuocytes when cul‑
tured on DLL1‑expressing OP‑9 cells in the presence of 
IL‑7 and IL‑33. In the absence of DLL1‑mediated Notch 
signalling, these progenitors develop into B cells, sug‑
gesting that Notch signalling is required at least for the 
in vitro generation of nuocytes. It remains to be investi‑
gated whether the in vivo development or expansion of 
these cells is also dependent on or influenced by Notch 
signalling. Although DN1 and DN2 thymocytes retain 
the potential to develop into nuocytes in vitro, forkhead 
box N1 (FOXN1)nu/nu mice (which lack a thymus) have 
normal nuocyte numbers; this indicates that in vivo these 
cells are likely to develop at extrathymic sites, such as the 
bone marrow58.
Taken together, these studies reveal that Notch 
signalling can influence the development and/or expan‑
sion of certain subsets of ILCs, which is probably also 
microenvironment dependent (FIG. 2). Future studies 
will be necessary to more specifically address the in vivo 
requirements and specific receptor–ligand interactions 
that are necessary for the development and function 
of certain ILC subsets.
Notch and helper T cell functions
During immune responses, naive CD4+ T cells encounter 
antigens in peripheral lymphoid organs. Recognition of 
cognate peptide antigens presented by antigen‑presenting 
cells (APCs) triggers clonal T cell expansion and their dif‑
ferentiation into several functionally distinct CD4+ TH cell 
subsets. Each TH cell subset secretes a specific pattern of 
effector cytokines that coordinates immune responses 
against various types of pathogens and also has an impor‑
tant role in autoimmune inflammatory diseases. The most 
well‑characterized TH cell subsets include TH1 cells, TH2 
cells59, TH17 cells
60,61 and regulatory T (TReg) cells
62, as well 
as the more recently described TH9 cells
63,64 and follicu‑
lar T helper (TFH) cells
65,66. Although these TH cell subsets 
were long thought to be fixed lineages, some plasticity in 
the pattern of cytokines that they secrete may occur dur‑
ing the course of infection, a process that would allow a 
specific TH cell subset to react to changing environmental 
conditions67,68. Among the several factors contributing to 
the differentiation of naive CD4+ T cells towards a given 
TH cell subset, accumulating data indicate a crucial role for 
Notch signalling. However, the mechanisms involved have 
been somewhat controversial69–71. We discuss below recent 
advances in our understanding of the role for Notch in 
the differentiation and/or function of CD4+ TH cells.
Role of Notch ligands in TH cell differentiation and 
function. The induction of specific Notch ligands by 
pathogen‑derived signals has a profound impact on the 
differentiation or function of CD4+ T helper cells. A cor‑
relation between the type of Notch ligand expressed on 
APCs and the development of TH1 and TH2 cells was 
first reported by Flavell and colleagues72 and further 
extended by different groups to these and other TH cell 
Figure 2 | The role of Notch signalling in the development of innate lymphoid cells. 
Haematopoietic stem cell (HSC)-derived common lymphoid progenitors (CLPs) give rise 
to adaptive immune cells, such as T cells and B cells, as well as to innate lymphoid cells 
(ILCs) that do not express antigen receptors. ILCs fulfil important functions in innate 
immune responses through their ability to generate and secrete different cytokines  
and/or to exhibit cytotoxic activity. They can be grouped into three major classes:  
group 1, group 2 and group 3 (REF. 47). ILCs diverge in their requirement for Notch (as 
indicated). AHR, aryl hydrocarbon receptor; IL, interleukin; LTi, lymphoid tissue-inducer; 
NK, natural killer; ROR, retinoid-related orphan receptor.
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γ-secretase inhibitors
These are small-molecule 
inhibitors that block the S3 
cleavage of Notch receptors, 
thereby inhibiting the liberation 
of the Notch intracellular 
domain (NICD) and the 
activation of the Notch 
signalling cascade.
subsets. Studies carried out both in vitro and in vivo 
convincingly showed that the engagement of Delta‑like 
Notch ligands favours the development of interferon‑γ 
(IFNγ)‑secreting TH1 cells, whereas the engagement of 
Jagged ligands preferentially induces the development of 
TH2 cells and TReg cells (reviewed in detail in REFS 71,73). 
The type of Notch ligands involved in the differentiation 
of other TH cell populations awaits further studies.
The impact of Notch on TH1 cell function in vivo. The 
impact of Notch receptor triggering on TH cell dif‑
ferentiation or function was first investigated using 
well‑defined in vitro TH cell polarization conditions.
The numerous studies performed did not provide 
conclusive evidence for a role for Notch signalling 
during TH cell differentiation
69,71. The importance of 
Notch signalling on TH cell differentiation or function is 
better documented by an increasing number of studies 
carried out in vivo.
The role of Notch in the differentiation of IFNγ‑
secreting TH1 cells in vivo has been investigated using 
several approaches designed to inhibit Notch signalling. 
Treatment of mice with γ-secretase inhibitors impeded 
disease progression in TH1 cell‑mediated experimental 
autoimmune encephalomyelytis (EAE)74,75. It was hypoth‑
esized that Notch 1 could bind to an RBPJ‑binding 
sequence on the T‑box 21 (Tbx21) gene promoter, which 
encodes T‑bet, the master regulator of TH1 cell differen‑
tiation74; however, such binding of Notch to the Tbx21 
gene was not confirmed in another study76. Targeting 
γ‑secretase may not only affect Notch cleavage but may 
also affect the cleavage of many other targets that could 
affect TH cell differentiation independently of Notch 
signalling, emphasizing the importance of using vari‑
ous experimental approaches to block Notch signalling. 
In contrast to the results obtained following γ‑secretase 
treatment, functional TH1 cells could develop in response 
to infection in mice that do not activate RBPJ because 
of dominant‑negative MAML expression77. In the same 
line, mice deficient for RBPJ expression in their T cells 
were also able to mount a protective TH1 cell response 
following infection with the parasite Leishmania major78. 
Altogether, these studies suggest that TH1 cell differentia‑
tion does not involve canonical Notch signalling, defined 
as the association of the Notch intracellular domain 
(NICD) with RBPJ in the nucleus. Several partners could 
interact with Notch during non‑canonical signalling in 
peripheral T cells. Subunits of the NF‑κB transcription 
factor were identified as potential Notch partners79,80, and 
further research is needed to characterize the interactions 
of Notch with NF‑κB (FIG. 3a).
To further study the impact of Notch on TH cell dif‑
ferentiation, Notch receptors were inactivated by genetic 
deletion in T cells or were blocked using monoclonal 
antibodies directed against Notch 1 or Notch 3. In a 
model of passively transferred EAE, the adoptive transfer 
of lymph node cells treated with Notch  3‑specific 
neutralizing antibodies, but not with Notch 1‑specific 
neutralizing antibodies, reduced the release of IFNγ 
and IL‑17 by myelin‑reactive cells, with a correspond‑
ing decrease in the EAE disease scores75. Of note, it was 
not possible to determine in this study whether the lower 
levels of IFNγ produced resulted from impaired TH1 cell 
differentiation and/or from impaired TH1 cell function.
Expression of Notch 1 (and compensatory expression 
of Notch 2 in the absence of Notch 1) on T cells is crucial 
for the differentiation of functional IFNγ‑secreting TH1 
cells during infection with L. major. Following parasite 
inoculation, Notch‑deficient naive CD4+ T cells dif‑
ferentiated into TH1 cells expressing Tbx21 mRNA and 
IFNγ proteins, but these cells were unable to secrete 
IFNγ78 (FIG. 3a). These data suggest that Notch signalling 
is involved in the control of TH1 cell effector functions, 
rather than in the differentiation of TH1 cells. Thus, 
Notch 1, Notch 2 and Notch 3 have each been individu‑
ally shown to affect the functions of TH1 cells in vivo, 
and it is possible that different Notch receptors may be 
involved in different TH1‑type contexts.
The impact of Notch on TH2 cell differentiation in vivo. 
Regulation of TH2 cell differentiation in vivo by Notch 
was documented in several experimental models81,82. In 
contrast to what was reported in TH1 cell differentiation, 
Notch signalling in TH2 cell differentiation was shown 
to be dependent on RBPJ (canonical Notch signalling). 
Several RBPJ‑binding sites were identified on the Il4 
enhancer (conserved non‑coding sequence 2 (CNS2); 
also known as HS5), suggesting a direct role of Notch in 
IL‑4 transcription in TH2 cells, NKT cells and possibly 
other IL‑4‑secreting cells72,82. As IL‑4 is a master regulator 
of TH2 cell differentiation, Notch signalling may thereby 
promote TH2 cell differentiation by both cell‑intrinsic and 
cell‑extrinsic mechanisms. In addition to its direct regu‑
lation of Il4, Notch was reported to bind to the promoter 
of GATA‑binding factor 3 (GATA3), a master regulator 
of TH2 cell differentiation
83, thus inducing the expression 
of the Gata3 exon 1a transcript83. Both Notch 1 and RBPJ 
were shown to bind close to the Gata3 promoter, and 
GATA3 activity was required for the Notch‑dependent 
induction of IL‑4, suggesting a synergy between both 
pathways76,81. Expression of GATA3 from the exon 1b 
transcript was shown to be independent of Notch. The 
conditions determining the selective usage of either 
GATA3 exon 1a or exon 1b transcripts and the need for 
Notch in TH2 cell differentiation remain to be defined 
and are likely to be context dependent (FIG. 3b).
The impact of Notch on other TH  cell subsets in vivo. The 
Notch signalling pathway was also shown to cooperate 
with TGFβ to induce TH9 cells
84. Interaction between 
SMAD3, a TGFβ target protein, and RBPJ resulted in 
the induction of the IL‑9 promoter. Mice deficient in 
Notch 1 and Notch 2 in their T cells developed milder 
EAE compared with control mice, and both IL‑9 and 
IL‑17 cytokine production was decreased upon anti‑
genic re‑stimulation in vitro. This suggested that Notch 
signalling is regulating TH9 cell function during EAE. 
However, although the impact of Notch signalling on 
EAE is well documented, it is difficult to evaluate the 
impact of Notch on individual TH subsets during EAE 
owing to the plasticity among TH subsets (TH17, TH1, TH9 
and TReg cells) that develops during the disease
85.
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Altogether, increasing evidence reveals that Notch 
signalling considerably influences the development of 
immune responses by acting on the differentiation or 
function of different TH subsets (FIG. 3). Better under‑
standing of the mechanisms involved in these processes 
will allow the design of appropriate strategies to favour 
or prevent the development of a TH cell subset during 
pathologies in which these T cells have important roles.
Notch and regulatory T cell functions
TReg cells have important functions in the maintenance of 
peripheral self‑tolerance and in the modulation of vari‑
ous polarized TH cell immune responses. There are two 
main types of TReg cell: TReg cells that develop in the thymus 
(thymic TReg cells) and TReg cells that develop in the periph‑
ery from naive CD4+ T cells (peripherally induced TReg 
cells). Common features of TReg cells are their expression 
of the transcription factor FOXP3 and their suppression 
or control of pro‑inflammatory immune responses86.
The first indications that Notch signalling could be 
involved in TReg cell function originated from studies 
showing that CD4+ splenic T cells positive for CD25, a 
molecule expressed by TReg cells, express higher levels of 
Notch 3 receptor than do CD4+CD25− wild‑type cells, 
and that transgenic expression of intracellular, constitu‑
tively active Notch 3 in T cells induced the accumula‑
tion of TReg cells in the thymus and periphery, leading to 
protection against experimentally induced autoimmune 
diabetes in mice87. Further studies by this group reported 
that Notch 3 promoted the development of TReg cells and 
improved their suppressive activity by upregulating 
FOXP3 expression88,89. In a more physiological setting, 
TReg cell exposure to Jagged 2‑expressing haematopoietic 
progenitors induced the activation of Notch 3 signal‑
ling and promoted the expansion of TReg cells that could 
prevent disease onset in an experimental type 1 diabetes 
model90. Collectively, these studies indicate an important 
role for Notch signalling in the expansion of TReg cells.
Figure 3 | Role of Notch in T helper 1 and T helper 2 cell differentiation and function. T helper (T
H
) cell-promoting 
signals induce the expression of Notch ligands (Delta-like ligands (DLLs) or Jagged) on antigen-presenting cells (APCs). 
a | T
H
1 cell-promoting signals induce the expression of DLLs and the release of the Notch intracellular domain (NICD), 
which can bind to the nuclear factor-κB (NF- κB) family proteins p50 and p65. In addition, the NICD can control the release 
of interferon-γ (IFNγ) either directly or indirectly. b | T
H
2 cell-promoting signals induce the expression of Jagged ligands 
and the release of the NICD, which interacts with recombination signal-binding protein for immunoglobulin κJ region 
(RBPJ), converting it to a transcriptional activator. RBPJ recruits co-activators (CoAs) and the complex binds and 
transactivates the promoter of GATA binding protein 3 (GATA3), transcribing exon 1a. Interleukin-4 (IL-4) can also initiate 
T
H
2 cell differentiation by triggering signal transducer and activator of transcription 6 (STAT6), which induces the 
transcription of Gata3. Transcription of Gata3 exon 1b is Notch independent. Gata3 and Il4 expression reinforce GATA3 
expression. GATA3 modifies the conformation of the Il4, Il5 and Il13 loci, allowing their transcription. Notch 1 is the 
predominant pathway used (indicated in bold). Dashed arrows represent hypothetical pathways. IL-4R, IL-4 receptor. 
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Neutralization of DLL4 during the induction of EAE 
resulted in an increase in the number of peripherally 
induced TReg cells with a corresponding decrease in dis‑
ease severity91. The effect was specific to DLL4, as DLL1 
blockade had no effect on TH17 and TReg cell differen‑
tiation during EAE92. In addition, a more recent study 
showed that anti‑DLL4 treatment prevented the devel‑
opment of, and even reverted, type 1 diabetes in non‑
obese diabetic (NOD) mice by inducing an increase in 
the number of DC‑dependent de novo thymic TReg cells
93. 
Taken together, these results demonstrate an essential 
role for DLL4‑mediated immune regulation in the con‑
trol of both thymic TReg cell and peripherally induced 
TReg cell homeostasis, although mechanistic details 
remain to be elucidated. Blocking Notch ligands could 
be a strategy to selectively regulate TReg cell prolifera‑
tion. Increasing data suggest that the selective blocking 
of DLL4‑mediated Notch signalling ameliorates multiple 
forms of experimental autoimmunity via the regulation 
of TReg cells (BOX 2).
Jagged‑mediated Notch signalling is also important 
in the control of peripherally induced TReg cell differen‑
tiation. TGFβ induces FOXP3 expression in peripheral 
naive T cells, allowing their differentiation into periph‑
erally induced TReg cells
62,94. A role for Notch signalling 
in peripherally induced TReg cell differentiation was first 
suggested by several experiments showing that over‑
expression of the Notch ligand Jagged 1 on APCs led to 
peripherally induced TReg cell differentiation both in vitro 
and in vivo95,96. The peripheral induction of TReg cells by 
Notch signalling was shown to involve the activation 
of FOXP3, the master transcription factor of TReg cells. 
Notch 1 co operates with SMAD3 (a mediator of TGFβ 
signalling) and RBPJ to activate FOXP3 transcription5,97. 
Accordingly, in vivo treatment of mice with γ‑secretase 
inhibitors reduced the TGFβ‑mediated induction of 
FOXP3, decreased peripherally induced TReg cell devel‑
opment and maintenance, and led to the development of 
auto immune hepatitis5. The importance of Notch signal‑
ling in ensuring sustained FOXP3 expression and main‑
tenance of peripherally induced TReg cells was recently 
confirmed in human cells98. Pluripotent stem cells trans‑
duced with FOXP3 and co‑cultured on Notch ligand‑
expressing stromal cells generated stable TReg cells in vitro
99, 
suggesting that this could be a strategy for producing 
stable TReg cells for therapeutic adoptive transfer.
Collectively, increasing experimental evidence 
demonstrates a crucial role for Notch signalling in the 
expansion of thymic TReg cells, in the differentiation of 
peripherally induced TReg cells and in the maintenance of 
both of these TReg cell populations. However, more direct 
loss‑of‑function experiments will be required to validate 
these conclusions.
Notch, cytotoxic T cells and GVHD
Notch signalling promotes cytotoxic T lymphocyte dif-
ferentiation. Both CD4+ and CD8+ T cells are required 
to eliminate many intracellular pathogens. Upon recog‑
nition of antigens presented by MHC class I‑expressing 
cells, naive CD8+ T cells multiply and differentiate into 
cytotoxic T lymphocytes (CTLs). Effector functions of 
CTLs include the secretion of IFNγ, the lysis of target 
cells using perforins and granzymes, and the induction 
of target cell apoptosis through FAS–FAS ligand (FASL) 
interactions. A role for Notch in the differentiation of 
CD8+ T cells is supported by several studies.
The ligation of Notch ligands was shown to affect 
the differentiation of CTLs. DLL1 ligation by Notch 
expressed on splenic CD8+ T cells changed their patterns 
of cytokine secretion, decreasing their production of 
IFNγ and increasing their production of IL‑10 (REF. 100). 
In addition, CD8+ T cells exposed to allogenic DCs 
transduced with DLL1 showed increased granzyme B 
production and lysed target cells more efficiently in vitro, 
suggesting that DLL1‑induced signalling contributes to 
CTL differentiation in vivo101. DLL1 blockade similarly 
decreased the frequency of granzyme B‑producing 
CTLs, and lower cytotoxic activity of CD8+ T cells was 
observed in a transplantation model102.
Notch 2 expression on CD8+ T cells was reported 
to promote CTL differentiation and to directly regulate 
granzyme B and perforin expression both in vitro and 
in vivo, demonstrating a crucial role for Notch signal‑
ling in CD8+ T cell cytotoxic responses. Notch 2 formed 
a complex with phosphorylated cyclic AMP‑responsive 
element‑binding protein 1 (pCREB1) and the transcrip‑
tional co‑activator p300 on the granzyme B (Gzmb) pro‑
moter101. The same group later reported that Notch 2 
signalling, but not Notch 1 signalling, was required 
for the generation of antitumour CTL responses103. 
Further indication for a role of Notch signalling in 
CTL effector functions was reported using γ‑secretase 
inhibitor treatment, which blocked the expression of the 
T‑box eomesodermin (EOMES) transcriptional factor, 
thus reducing perforin and granzyme B expression. 
Box 2 | Notch and autoimmune disease
Autoimmune diseases such as multiple sclerosis and type 1 diabetes arise from 
inappropriate immune responses against self antigens, leading to the selective destruction 
of particular cell types or tissues. These inappropriate immune responses involve both 
adaptive and innate immune cells. As Notch signalling is involved in the regulation of 
peripheral immune responses, multiple groups have investigated the outcome of 
manipulating Notch signalling in experimental autoimmune disorders. Experimental 
autoimmune encephalomyelitis (EAE) is a frequently used mouse model for multiple 
sclerosis117. This inflammation-mediated demyelination disease of the central nervous 
system (CNS) can be induced by immunization with myelin antigens, viral infection or 
transfer of autoreactive T cells. Genetic and pharmacological interference with Notch 
signalling, as well as administration of blocking antibodies against Notch receptors or 
Delta-like ligand 4 (DLL4), impeded progression of the disease, resulting in reduced  
clinical severity74,75,84,91,92,118–119. The mechanisms by which blockage of Notch signalling 
ameliorates EAE are not fully understood and require further investigation. Possibilities 
include impaired T helper 1 (T
H
1)-type and T
H
17-type immune responses91; impaired 
migration of antigen-specific CD4+ T cells to the CNS as a consequence of 
downregulation of chemokine receptors119; and/or promotion of regulatory T cell 
development91. Similar observations have been reported in a more recent study  
using non-obese diabetic (NOD) mice as a model for type 1 diabetes. In these  
mice, pancreatic β-cells are selectively destroyed through autoreactive T cells. 
Administration of DLL4-specific antibodies prevented the development of type 1 
diabetes and in some cases even caused the reversion of already established  
disease by inducing de novo expansion of regulatory T cells93. Taken together,  
these preclinical studies indicate that selective blocking of DLL4-mediated Notch 
signalling may ameliorate multiple forms of autoimmunity.
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Treatment with γ‑secretase inhibitors did not affect 
the FAS–FASL interactions of CTLs. Notch 1 antisense 
(Notch1 AS) mice, which have reduced expression of 
Notch 1, also showed reduced EOMES, perforin and 
granzyme B expression, suggesting that Notch 1 signal‑
ling is involved in CTL differentiation104. The nature of 
the Notch receptor involved (Notch 1 or Notch 2) may 
vary depending on the experimental context. A recent 
study reported a role for Notch also in the generation 
and function of human CD8+ T cells, suggesting that its 
role in this particular subset of T cells is conserved105.
Collectively, these experiments show an important 
role for Notch signalling in the differentiation of func‑
tional CTLs. The implication of Notch signalling in 
the generation of memory CD8+ T cells has not been 
investigated yet and should be of interest.
Notch signalling in GVHD. More recent evidence also 
suggests a role for the Notch cascade in regulating graft‑
versus‑host disease (GVHD) following allogeneic bone 
marrow transplantation (allo‑BMT). Patients with leu‑
kaemia and patients with lymphoma have to undergo 
allo‑BMT in cases in which tumour cells cannot be eradi‑
cated by chemotherapy. The goal of allo‑BMT is that 
transplanted donor T cells mediate graft‑versus‑tumour 
(GVT) activity and thereby kill the cancer cells. However, 
GVT activity is often associated with GVHD because 
donor T cells also react against normal host tissue. This 
represents one of the major complications of allo‑BMT 
in patients with cancer. Although these patients can 
subsequently be treated with immunosuppressive drugs 
to decrease the risk of GVHD, it comes at the price of 
impairing GVT activity. Such patients have a higher risk 
of undergoing tumour relapse, which compromises their 
overall survival106.
In this context, preclinical studies were used to evalu‑
ate the function of Notch signalling in T cells in mouse 
models of allo‑BMT settings using genetic loss‑of‑ 
function approaches. Expression of a dominant‑neg‑
ative form of MAML1 (which blocks canonical Notch 
signalling of all receptors) in donor T cells resulted in 
near complete protection from acute GVHD in multi‑
ple models of allo‑BMT (including major antigen mis‑
matched models, such as transplantation of C57Bl/6 
bone marrow into BALB/c hosts). More importantly, 
these Notch signalling‑incompetent T cells retained cyto‑
toxic and anti‑leukaemic activity, leading to substantially 
improved overall survival of host animals challenged 
with a B cell‑lineage lymphoma. The protection against 
GVHD in this experimental setting was not mediated by 
an overall immunosuppression, as the Notch‑deficient 
alloreactive T cells exhibited normal in vivo proliferative 
responses107. However, T cells expressing the dominant‑
negative‑MAML1 mutant or lacking RBPJ produced 
reduced levels of multiple inflammatory cytokines, 
including IFNγ, IL‑4, IL‑17, tumour necrosis factor and 
IL‑2, compared with wild‑type T cells. Interestingly, the 
levels of T‑bet and EOMES, which are, respectively, master 
regulators of TH1 cell and effector CD8
+ T cell differen‑
tiation, were unchanged in Notch signalling‑deficient 
T cells107. This argues against a simple differentiation 
defect of helper or effector T cells as a consequence of loss 
of Notch signalling. A more recent study from the same 
group in which blocking antibodies were used revealed 
that the beneficial effect of inhibiting Notch signalling in 
models of GVHD is mediated via the specific blockade of 
Notch 1 and Notch 2 on the receptor side and DLL1 and 
DLL4 on the ligand side. Blockage of individual recep‑
tors and ligands revealed dominant effects for Notch 1 
and DLL4. Importantly, the combined administration 
of DLL1‑specific and DLL4‑specific antibodies pro‑
vided long‑lasting protection against GVHD without 
any apparent gut toxicities, such as those observed using 
blocking antibodies against the Notch receptors. The pro‑
tection correlated with the persistent expansion of TReg 
cells108. Although the elucidation of the precise mecha‑
nism requires further investigation, the impressive effects 
of blocking Notch signalling in mouse models of GVHD 
indicate a strong potential for clinical translation.
In addition to the role of Notch in alloreactive T cells, 
recent work suggests that Notch signalling in DCs can 
also influence GVHD109. Ikaros is a transcriptional 
repressor that in some contexts functions as a nega‑
tive regulator of Notch signalling110,111. Ikaros‑deficient 
bone marrow chimaeras revealed an enhanced GVHD 
in multiple models of allo‑BMT compared with con‑
trol animals. Ikaros deficiency resulted in upregulation 
of multiple Notch receptors, ligands and Notch target 
genes in DCs. Allogeneic T cells proliferated more when 
co‑cultured with Ikaros‑deficient DCs compared with 
when they were co‑cultured with wild‑type DCs, but this 
increased proliferation was reverted following the treat‑
ment of T cells with γ‑secretase inhibitors to block Notch 
signalling. More importantly, allogeneic Ikaros‑deficient 
bone marrow chimaeras treated with γ‑secretase 
inhibitors in vivo showed a significantly diminished 
GVHD pathology compared with vehicle‑treated con‑
trol chimaeras109. It remains to be investigated whether 
Notch signalling in wild‑type DCs influences GVHD. 
However, taken together, these reports show that block‑
ing Notch signalling ameliorates GVHD in allo‑BMT 
models, whereas GVT activity is preserved.
Conclusion and perspectives
During the past decade the Notch cascade has emerged as 
an important regulator of multiple cell fate decisions and 
differentiation processes during the development and 
function of the haematopoietic system. Among the most 
well‑established functions of Notch are its essential roles 
in the specification and maturation of T cells, as well as of 
MZB cells. For these two lymphoid lineages, the relevant 
receptor–ligand pairs have been identified by conditional 
genetic loss‑of‑function approaches. T cell lineage com‑
mitment and maturation is mediated by DLL4–Notch 1 
interactions, and MZB cell development is mediated 
by DLL1–Notch 2 interactions. Both of these processes 
use canonical (that is, RBPJ‑dependent) Notch signal‑
ling. More recently, a role for Notch during development 
and/or expansion of ILCs has been identified. The role 
of Notch in ILCs has been inferred from multiple stud‑
ies through the requirement of DLL‑expressing feeder 
cells to generate ILCs in vitro. However, conditional 
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inactivation of RBPJ has clearly demonstrated that Notch 
signalling is required in vivo for the development and/or 
expansion of NKp46+ ILCs within the lamina propria 
of the intestine. Additional loss‑of‑function studies 
will be required in the future to establish the in vivo 
relevance of Notch in ILCs, as well as for elucidating 
the ligand–receptor interactions that are involved.
Genetic loss‑of‑function experiments also show an 
important role of Notch signalling in both TH2 cell dif‑
ferentiation and TH1 cell function. Experimentally, 
Jagged or DLL expression on APCs has been associated 
with TH2 cell and TH1 cell differentiation, respectively. 
Genetic, pharmacological and antibody‑based block‑
age of specific ligands and receptors confirmed the role 
of DLL‑mediated Notch signalling in TH1 cell function. 
Interestingly, this is a process that does not require canoni‑
cal RBPJ‑mediated signalling. By contrast, TH2 cell differ‑
entiation is dependent on canonical Notch signalling. It is 
still generally unknown how Jagged‑ and DLL‑expressing 
APCs differ in their ability to induce Notch signals and 
how this translates into the differentiation of TH cells.
Pharmacological Notch inhibitors and more specific 
blocking antibodies for individual Notch receptors and 
ligands were originally developed for anticancer therapy. 
These tools are now also being explored in the context 
of preclinical investigations of autoimmune diseases and 
GVHD. In particular, blocking Notch using DLL4‑specific 
antibodies ameliorated pathology in several experimental 
autoimmune disease models. Similarly, Notch blockade in 
allo‑BMT significantly reduced GVHD while preserving 
GVT activity. Although the exact mechanisms underlying 
these promising observations are not clear, they open the 
door to exploring these tools in immunological disorders 
in a clinical setting. Thus, Notch is an attractive target 
not only for cancer therapy but also for modulating the 
immune system during other pathological conditions.
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